Navigation Links
Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life

ielded through an online panel that closely reflects the U.S. adult population overall. Physicians were recruited from a list of all board certified gastroenterologists in the U.S. Assuming no sample bias, the margin of error for the sample of 451 UC patients is +/- 5 percent; assuming no sample bias, the margin of error for a sample of 300 (the other surveys) is +/- 6 percent.

For more information about the survey, visit http://www.UCNORMAL.com. For more information on ulcerative colitis, visit http://www.managinguc.com.

About UC

UC is a type of inflammatory bowel disease that produces chronic inflammation and sores or ulcers along the inside of the large intestine. Symptoms may include severe abdominal pain and cramping, frequent and sometimes uncontrollable bloody diarrhea, fatigue and weight loss. This chronic autoimmune disease is typically first diagnosed in people between the ages of 15 to 30 and is estimated to affect nearly 700,000 Americans. According to the National Institutes of Health, about five percent of people with UC will develop colon cancer.

About LIALDA

LIALDA is part of a drug class called aminosalicylates, which contain 5-aminosalicyclic acid (5-ASA). 5-ASA is a well-established drug of choice and often a first-line treatment for UC. LIALDA is indicated for the induction of remission in patients with active, mild to moderate UC. The safety and efficacy of LIALDA have been established for up to eight weeks. LIALDA is the first new formulation in this class to be approved since 2000. LIALDA is the only ulcerative colitis treatment that utilizes MMX(TM) Technology. LIALDA with MMX Technology combines a pH dependent gastro-resistant coating, which delays the release of the medication to the colon (the site of the inflammation in ulcerative colitis), with a tablet core containing mesalamine with hydroph
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
2. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
3. Long-Term Extension of Ulcerative Colitis Study Shows Remicade Responders Maintained Improvement Through Two Years of Follow-Up
4. Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term Safety Study of Lialda (mesalamine) Presented at DDW
5. Callisto Intends to Move Guanilib into Clinical Trials in Ulcerative Colitis
6. New Survey Finds Troubling Data on American Asthma Sufferers
7. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
8. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
9. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
10. International Movement Disorder Specialists Receive New Information About the Use of Once-Daily Azilect in the Treatment of Parkinsons Disease
11. New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia
Post Your Comments:
(Date:10/25/2014)... 2014  The National Association of Drug Diversion ... by Kentucky,s real-time, stop-sale ... National Precursor Log Exchange (NPLEx) system automatically blocks ... and helps flag meth offenders for law enforcement. ... NPLEx "watch lists" that notify them via email ...
(Date:10/25/2014)... 2014 Burzynski Research Institute, Inc. (BRI) announced ... has given the company permission to conduct an open-label ... 3 months of age with a diffuse intrinsic brainstem ... of five treatment groups based on their age and ... DIPG. The primary study endpoint is a decrease in ...
(Date:10/22/2014)... N.J. , Oct. 22, 2014  Rescheduling ... major transformation in the pain market, according to ... Insights, Inc., a firm providing market research and ... Photo - http://photos.prnewswire.com/prnh/20141021/153440 ... scheduling change for hydrocodone combination products from Schedule ...
Breaking Medicine Technology:Kentucky's NPLEx Technology Making Significant Progress 2Burzynski Research Institute, Inc. Announces FDA Permission to Launch a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma 2Hydrocodone: Rescheduled, Repositioned & Reinvented 2Hydrocodone: Rescheduled, Repositioned & Reinvented 3
... will be presented at the American College of,Cardiology's ... 2007 /PRNewswire-FirstCall/ -- CV,Therapeutics, Inc. announced today that ... study of ranolazine shows there was no,adverse trend ... study did not meet the primary efficacy endpoint. ...
... in Intestinal Adenomas Suggesting,Possible Beneficial Mediation in the ... 07, 2007 /PRNewswire/ -- NutraCea,announced today the results ... bran,on the number of intestinal adenomas in cancerous ... of the prestigious British,Journal of Cancer conducted at ...
Cached Medicine Technology:CV Therapeutics Announces Topline MERLIN TIMI-36 Results 2CV Therapeutics Announces Topline MERLIN TIMI-36 Results 3British Journal of Cancer Reports Preclinical Evidence of Positive,Effect of Rice Bran on Intestinal Cancer 2British Journal of Cancer Reports Preclinical Evidence of Positive,Effect of Rice Bran on Intestinal Cancer 3British Journal of Cancer Reports Preclinical Evidence of Positive,Effect of Rice Bran on Intestinal Cancer 4
(Date:10/25/2014)... global HCIT outsourcing market is forecast to grow at ... 2018 from $35 billion in 2013. The health insurance ... the HCIT outsourcing market. These industries follow the HCIT ... reduce operational and maintenance costs, increase access to IT ... costs), share risk, and quickly implement new technologies. , ...
(Date:10/25/2014)... Hartford, CT (PRWEB) October 25, 2014 Background: ... for Addiction Recovery (CCAR). He is a pioneer in the ... 30-year career in Connecticut's state treatment system and when he ... had nagged him while in public service. ... are making critical decisions concerning them? , 2. Can ...
(Date:10/25/2014)... October 25, 2014 Market ... Diagnostics Industry, 2009-2019 is a professional and ... Molecular Diagnostics industry. The report firstly reviews ... its classification, application and manufacturing technology. The ... manufacturers of Molecular Diagnostics listing their product ...
(Date:10/25/2014)... (PRWEB) October 25, 2014 The ... ( http://www.vaginalmeshlawsuit2015.com/ ) filed against Boston Scientific ... U.S. District Court, Southern District of West Virginia ... on Punitive Damages in a group of cases ... ruling issued on October 21st, U.S. District Judge ...
(Date:10/25/2014)... supply to an arm or a leg before heart surgery ... to a new study. "During heart surgery we ... be able to operate on it. After some time without ... energy because it doesn,t get oxygen. When we shut off ... arm or a leg, the body prepares for an upcoming ...
Breaking Medicine News(10 mins):Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 2Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 3Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 4Health News:CCAR Accepting Nominations for the Bob Savage Recovery Advocate of the Year Award 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 3Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 4Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2
... case which took Spain by storm for 2 years, has ... been convicted to around 2000 years in prison for knowingly ... doctor worked in the Valencia area of Spain during 1988 to ... C. ,Maeso who carries the virus too , ...
... of chemo patients, scientists at the Georgia Institute of Technology ... , p53, thought to be essential in helping chemotherapy kill ... researchers found that 70 percent of subjects whose tumors had ... years. Patients with normal p53 displayed only a 30 percent ...
... Technology has revealed that airborne viruses can spread far and ... International Laboratory for Air Quality and Health, said the study ... a metre in the air. ,Professor Morawska ... way droplets carrying viruses are dispersed in the air when ...
... has found that women are significantly less likely than ... levels . ,Elevated LDL cholesterol is an ... single cause of death for both women and men. ... Care for Cardiovascular Disease: Using National Managed Care Performance ...
... may be a biological indicator of the trauma that ... by peers. ,The researchers believe that ... intervention of long-term psychological effects on youth. ... observed by teachers,' said JoLynn V. Carney, Associate Professor ...
... of small breast cancer may be a safe procedure ... according to a recent case report by radiologists at ... presents a case of an 85-year-old woman with two ... therapy, chemotherapy or chemoprevention therapy, says Gale A. Sisney, ...
Cached Medicine News:Health News:Killer Anesthetist Sentenced To 1933 Years In Prison 2Health News:Gene Thought to Help Kill Cancer Cells may Actually Help Them Thrive 2Health News:Out of Reach may Not Always Save You from Catching Cold 2Health News:Women Less Likely to Control LDL Cholesterol Levels Than Men 2Health News:Saliva Helps to Identify Child Victims of Chronic Bullying 2
... RUBYstar enables highly sensitive time-resolved fluorescence ... cryptate fluorophores. These compounds are excited ... long fluorescence lifetimes (several hundred microseconds), ... peak profiles at 620 nm. Therefore ...
... Evolution, Tecans most advanced multi-functional microplate ... of detection performance without compromising flexibility. ... latest development on the Ultra instrument ... options which adds to the flexibility ...
... OPTIMA is a fully automated microplate ... different measurement principles:, , Fluorescence Polarization ... Fluorescence , High-Performance Luminescence (flash ... ,It is designed for the ...
... a flexible multifunction plate reader that offers ... fluorescence intensity, time-resolved fluorescence, high-perfomance luminescence and ... with injectors that deliver reagent at the ... cell assays can be performed easily and ...
Medicine Products: